DNP Establishes Second Overseas R&D Base in IIT Hyderabad, India

March 23, 2026

Tokyo, March 23, 2026, Dai Nippon Printing Co., Ltd. (DNP) will establish a new research and development base in Telangana, India, in April 2026, to advance and reinforce its global R&D strategy. The base will be our second overseas after the one established in the Netherlands in September 2025.

DNP will proceed the joint research with the Indian Institute of Technology Hyderabad (IITH), a leading science and engineering university in India, in the mobility and medical healthcare fields, which are focus business areas for DNP. By establishing a base at the Technology Research Park (TRP), a corporate collaboration facility on the university campus, we aim to accelerate R&D outcomes and their social implementation by combining IITH's strength in human resources and R&D with DNP's technological capabilities.

The Indian market is gaining prominence in the global economy, driven by population growth and economic development. In recent years, amid moves to restructure supply chains, its importance as a research and development, and manufacturing hub has been increasing. India is also strategically located for business expansion into the Middle East and Africa regions.

Hyderabad, a city in Telangawa where DNP has chosen for this base, boasts an expanding and diverse technology industry ecosystem, including mobility and healthcare, along with data centers and semiconductor facilities.

The state of Telangana, where Hyderabad is located, is home to Telangana Mobility Valley (TMV), India's first dedicated mobility cluster, the aim of which is to promote the social implementation of next-generation mobility technologies. Hyderabad is also one of India's leading cities, with numerous pharmaceutical-related manufacturing facilities and a concentration of companies and human resources with strengths in pharmaceutical precision organic chemical synthesis technology.

By leveraging Hyderabad’s strengths in mobility demonstration and pharmaceutical industry infrastructure, DNP will accelerate the activities from R&D to social implementation in mobility and healthcare.

At this Indian base, we will initially conduct R&D in the areas of "wireless power supplies for electric vehicles (EVs)" and "active pharmaceutical ingredients (APIs)."

DNP currently holds the largest global market share for battery pouches (exterior materials) for EV lithium-ion batteries, and is also pursuing technology development related to next-generation mobility.

At the new base, looking ahead to a future society of autonomous driving and advanced mobility, DNP will utilize its sheet-type coil technology as a foundation for advancing the design, development, and commercialization of wireless power supply systems for EVs jointly with IITH. Through iterative demonstration trials and product refinement aligned with local needs, we will contribute to EV adoption and market expansion in India.

In the medical healthcare, through joint research with IITH, we will advance the development of synthesis routes for APIs. Leveraging the knowledge of precision organic chemical synthesis and process development amassed by DNP Fine Chemicals Utsunomiya Co., Ltd., a DNP Group company, DNP will advance development from synthesis route design through prototyping and evaluation to mass production.

In the future, we aim to position India as one of our global development bases for APIs, commercialize R&D outcomes, and pursue sales in India and other markets around the world.

DNP will further advance the globalization of its R&D to expand its overseas business. We will leverage the technologies and knowledge developed and acquired at this new R&D base in India to expand our operations, thereby strengthening the business portfolio of the entire DNP Group.